AEGiS-GMHC: Daiichi KS Drug

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Daiichi KS Drug

TREATMENT ISSUES, Volume 6, Number 8 - September, 1992; The Gay Men's Health Crisis Newsletter of Experimental Therapies
David Gold

On August 7,1992, activists from GMHC, ACT UP/ NY, ACT UP/Golden Gate and WHAM met with representatives from Daiichi Pharmaceuticals to discuss plans for SP-PG (now known as DS-4152), a compound which has shown promising results against Kaposi's sarcoma-like and solid tumor diseases in animals. Company officials disclosed plans to seek FDA approval for phase I trials in October 1992. These dose-escalating trials are planned for San Antonio and Los Angeles. Activists demanded that the company meet with the FDA before October so that the trials can be approved and initiated as quickly as possible. On August 11, 1992, Daiichi informed activists that it had already begun initial discussions with the FDA and that submission of documents would begin shortly. It is hoped that this is the beginning of a more cooperative effort by Daiichi to work with activists for the rapid testing and development of this promising compound. Reports indicate that another promising drug for KS, AGM-1470, which is believed to work in a manner similar to SP-PG, is about to begin clinical trials at the National Cancer Institute.

Copyright (c) 1992. Treatment issues is published ten times yearly. All rights reserved. Non-commercial reproduction is encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: telnet:aegis.com www: www.aegis.com

9209
GM060807

Copyright © 1992 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .